Drugdu.com expert's response:

Characteristics of Medical Device Clinical Trials

1. Extreme Product Diversity

Active devices, passive implants, in vitro diagnostic (IVD) reagents, software, imaging equipment… each category requires nearly completely different trial protocols, endpoint definitions, and operational procedures.

2. Results Are Highly Operator-Dependent

This is the most prominent feature of device trials. Especially for surgical and implantable devices: the same product operated by different surgeons can yield drastically different outcomes. Therefore, the technical proficiency, training, and consistency of investigators are critical. You could say the trial results are co-determined by "the doctor + the device."

3. More Flexible but Often Simpler Designs

Common designs include parallel, paired, crossover, and single-arm. But many devices lack suitable controls, cannot be blinded (surgical devices/large equipment are very hard to blind), or are ethically unsuitable for randomization — so a large proportion are single-arm/single-group trials. Protocols are typically much "thinner" than drug trials.

4. Smaller Sample Sizes and Shorter Durations

Many devices don't require the large-scale multicenter setups that drugs do. Sample sizes from dozens to a few hundred are common; durations are typically months to two to three years, rarely stretching beyond five years like some drug trials.

5. No Unified Phase I–IV Framework

Drugs have a clear progression: Phase I (safety) → Phase II (efficacy exploration) → Phase III (confirmatory) → Phase IV (post-market). Devices don't follow this model. Instead, they revolve around registration needs with a single "clinical evaluation/clinical trial."

6. Clinical Trials Can Be Waived for Some Products

Products with clear mechanisms of action, sufficient data from predicate devices, or safety/efficacy demonstrable through non-clinical means can be exempted from clinical trials — something that virtually doesn't exist in the drug world.

7. Risk-Based Pathways Differ by Classification

Class I filings generally require no clinical data; Class II mostly don't need or only need small-scale clinical data; Class III generally require clinical trials, some of which need NMPA approval before being conducted at Grade-A tertiary hospitals.

Core Differences from Drug Clinical Trials

First, product standardization is completely different.

The same batch of a drug shipped to Beijing or Guangzhou has virtually identical composition, dosage, and administration method. But the same surgical device or imaging equipment can produce very different operating procedures and results in different hospitals and different hands. Drugs are "standardized products"; devices are more like "standardized product + non-standardized operation" combined.

Second, operator dependence is worlds apart.

In drug trials, a nurse gives an injection or a doctor prescribes — the impact of the operator on endpoints is relatively controllable. In device trials, especially surgical and active devices, the operator themselves are part of the "variable" — something rarely seen in drug trials.

Third, blinding and randomization are much harder to achieve.

Drug trials can easily achieve double-blind designs with placebos and double-dummy techniques. Devices? You can't give a patient scheduled for knee replacement a "fake surgery" (although sham surgery exists, it carries huge ethical controversy), nor can you easily blind a large piece of equipment. So open-label and single-arm designs are far more common in device trials than in drug trials.

Fourth, the evaluation dimensions are broader.

Drugs mainly look at efficacy and safety (plus PK/PD, dose-response). Devices, in addition to safety and effectiveness, also need to evaluate operability, learning curve, non-inferiority/superiority versus current standard of care, user experience, etc. — more dimensions, more complexity.

Fifth, the regulatory logic is different.

Drugs have a clear Phase I–IV progression, with extensive Phase IV and real-world study requirements post-market. Devices don't have this phased model; they emphasize "one registration trial + post-market surveillance." Post-market oversight relies mainly on adverse event monitoring and periodic risk assessment, rather than the systematic Phase IV approach used for drugs.

Sixth, sample sizes and durations differ significantly.

Drug Phase III trials routinely involve thousands of subjects, multinational multicenter setups, and take three to five years at minimum. Device trials with dozens to a few hundred subjects, a handful of centers, and completion in about a year are very common. There are exceptions (e.g., large implantable devices may also reach thousands), but the overall scale gap is substantial.

Seventh, clinical trial waivers exist only for devices.

Drugs virtually have no path to "skip clinical trials and go straight to market" (at best, accelerated approval). But because devices are so diverse and some have very clear mechanisms, regulators allow exemptions through predicate device comparison or sufficiently robust non-clinical data — a regulatory arrangement unique to devices.

One-sentence summary: Drug clinical trials verify "how a standardized molecule performs in the human body," while medical device clinical trials verify "whether a product plus a set of procedures works well in real clinical settings" — the former leans more toward "scientific experimentation," the latter is more of a hybrid of "engineering validation + clinical application."